Published manuscripts directly acknowledging the FHCRC SPORE in Ovarian Cancer, Pacific Ovarian Cancer Research Consortium, and/or NIH Grant P50 CA83636

2008

Submitted:

Sarkar D, Falcon S, Ritz J, Gentleman R. Modeling Gene Expression Data via Chromosome Bands. [Submitted to Bioinformatics].

Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW. Phase II trial of single agent Cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. [Submitted to J Clin Oncology].

In Press:

Feng, Q, Deftereos G, Hawes S, Stern J, Willner JB,  Swisher E, Xi L, Drescher CW, Urban N, Kiviat N. DNA Hypermethylation, Her-2/neu Overexpression and p53 Mutations in Ovarian Carcinoma Corresponding. [In Press, Gynecol Oncol].

Oron A, Jiang Z, Gentleman R. Gene Set Enrichment Analysis Using Linear Models and Diagnostics. [In Press, Bioinformatics].

Published:

Andersen MR, Goff B, Lowe K, Scholler N, Bergan L, Urban N. Combining a symptoms index with CA125 to improve detection of ovarian cancer. Cancer. 2008 Aug 1;113(3):484-9.

Kalli KR, Krco CJ, Hartmann LC, Goodman K, Maurer MJ, Yu C, Johnson EM, Erskine CL, Disis ML, Wettstein PJ, Fikes JD, Beebe M, Ishioka G, Knutson KL. An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer. Cancer Res. 2008 Jun 15;68(12):4893-901.

Knudsen BS, Vande Woude G. Showering c-MET-dependent cancers with drugs. Curr Opin Genet Dev. 2008 Apr 9; [Epub ahead of print].

Li Y, Yee C. IL-21 mediated FoxP3 suppression leads to enhanced generation of antigen-specific CD8+ CTL. Blood. 2008 Jan 1;111(1):229-35.

Lowe K, Shah C, Wallace E, Anderson G, Paley P, McIntosh M, Andersen M, Scholler N, Bergan L, Thorpe J, Urban N, Drescher C. Effects of Personal Characteristics on Serum CA125, Mesothelin, and HE4 Levels in Healthy Post-menopausal Women at High-Risk for Ovarian Cancer. Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2480-7.

Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J., O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8.

Nelson BH. The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev. 2008 Apr;222:101-16. Review.

Palmer C, Duan X, Hawley S, Scholler N, Thorpe JD, Sahota RA, Wong MQ, Wray A, Bergan L, Drescher CW, McIntosh M, Brown P, Nelson B, Urban N. Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLOS ONE. 2008 Jul 9;3(7):e2633.

Price ND, Foltz G, Madan A, Hood L, Tian Q. Systems biology and cancer stem cells. J Cell Mol Med. 2008 Jan-Feb;12(1):97-110.

Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, Urban N, Taniguchi T.  Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008 Feb 28;451(7182):1116-20.

Scholler N, Gross J, Garvik BM, Wells L, Liu Y, Loch C, Ramirez A, McIntosh MW, Lampe P, Urban N. Use of cancer-specific yeast-secreted in vivo biotinylated recombinant antibodies for serum biomarker discovery. Journal of Translational Medicine. 2008 Jul 24;6(1):41.

Scholler N, Lowe KA, Bergan LA, Kampani AV, Ng V, Forrest RM, Thorpe JD, Gross JA, Garvik BM, Drapkin R, Anderson GL, Urban N.  Use of yeast-secreted in vivo biotinylated recombinant antibodies (biobodies) in bead-based ELISA. Clinical Cancer Research. 2008 May 1;14(9):2647-55.

Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 2008 Apr 15;68(8):2581-6.

Walsh CS, Ogawa S, Karahashi H, Scoles DR, Pavelka JC, Tran H, Miller CW, Kawamata N, Ginther C, Dering J, Sanada M, Nannya Y, Slamon DJ, Koeffler PH, Karlan BY.  ERCC5 is a novel biomarker of ovarian cancer prognosis. J Clin Oncol. 2008 Jun 20;26(18):2952-8.

           

2007

Bergan L, Gross JA, Nevin B, Urban N, Scholler N. Development and in vitro validation of anti mesothelin biobodies that prevent CA125/mesothelin-dependant cell attachment. Cancer Lett.2007; 255 (2):263-74.

Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, Patras J, Mahoney BS, Andersen MR. Development of an ovarian cancer symptom index. Cancer. 2007; 109:221-7.

McIntosh MW, Liu Y, Drescher C, Urban N, Diamandis EP. Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. Clin Cancer Res. 2007;13(15 Pt 1):4422-8.

Scholler N, Garvik B, Hayden-Ledbetter M, Kline T, Urban N. Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery. Cancer Lett. 2007; 247 (1):130-6.

Simon I, Liu Y, Krall K, Urban N, Wolfert R, Kim N, McIntosh M. Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol Oncol. 2007; 106(1): 112-8.

Thorpe JD, Duan X, Forrest R, Lowe K, Brown L, Segal E, Nelson B, Anderson GL, McIntosh M, Urban N. Effects of blood collection conditions on ovarian cancer serum markers. PLoS ONE. 2007 Dec;2(12):e1281.

Urban ND, Longton GM, Crowe AD, Drucker MJ, Lehman CD, Peacock S, Lowe KA, Zeliadt SB, Gaul MA. Computer-Assisted Mammography Feedback Program (CAMFP): An electronic tool for continuing medical education. Academic Radiology. 2007 Sep;14(9):1036-42.

2006

Chiang JW, Karlan BY, Cass l, Baldwin RL. BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. Gynecol Oncol 2006; 101 (3):403-10.

Goodell V, Salazar LG, Urban N, Drescher CW, Gray H, Swensen RE, McIntosh MW, Disis ML. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol 2006;24: 762-8.

Hellstrom I, Raycraft J, Kanan S, Sardesai NY, Verch T, Yang Y, Hellstrom KE. Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev. 2006; 15 (5):1014-20.

Scholler N, Garvik B, Quarles T, Jiang S, Urban N. Method for generation of in vivo biotinylated recombinant antibodies by yeast mating. J Immunol Methods. 2006; 317 (1-2):132-43.

Scholler N, Crawford M, Sato A, Drescher CW, O'briant KC, Kiviat N, Anderson GL, Urban N. Bead-Based ELISA for Validation of Ovarian Cancer Early Detection Markers. Clin Cancer Res. 2006 Apr 1;12(7):2117-24.

2005

Andersen MR, Abullarade J, Urban N. Assertiveness with physicians is related to women's perceived roles in the medical encounter. Women Health. 2005;42(2):15-33.

Andersen MR, Schroeder T, Gaul M, Moinpour C, Urban N. Using a population-based cancer registry for recruitment of newly diagnosed patients with ovarian cancer. Am J Clin Oncol. 2005 Feb;28(1):17-20.

Li AJ, Lerner DL, Gapuzan ME, Karlan BY.  AIB1 polymorphisms predict aggressive ovarian cancer phenotype. Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2919-22.

Stewart JJ, White JT, Xiaowei Y, Collins S, Drescher CW, Urban N, Hood L, Lin B. Proteins associated with cisplatin resistance in ovarian cancer cells identified by quantitative proteomics technology and integrated with mRNA expression levels. Mol Cell Proteomics. 2005 Mar 1: 5(3): 433-43.

Tu S-P, Chen H, Chen A, Lim J, May S, Drescher C. Clinical trials: Understanding and perceptions of female Chinese-American cancer patients. Cancer. 2005;104: 2999-3005.

2004

McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, Hellstrom I. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol. 2004 Oct;95(1):9-15.

Yang S, Yang Y, Raycraft J, Zhang H, Kanan S, Guo Y, Ronai Z, Hellstrom I, Hellstrom, KE. Melanoma cells transfected to express CD83 induce anti-tumor immunity that can be increased by also engaging CD137. Proc Natl Acad Sci. 2004;101, 4990-5.

2003

Baldwin RL, Tran H, Karlan BY.  Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling. Cancer Res. 2003 Mar 15;63(6):1413-9.

Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellstrom KE.  The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003 Jul 1;63(13):3695-700.

Hellstrom KE, Hellstrom I. Therapeutic vaccination with tumor cells that engage CD137. J Mol Med. 2003; 81:71-86.

McIntosh MW, Urban N.  A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker. Biostatistics. 2003; 4:27-40.

Pepe MS, Longton G, Anderson G, Schummer M. Selecting Differentially Expressed Genes from Microarray Experiments. Biometrics. 2003; 59:133-42.

Stone B, Schummer M, Paley PJ, Thompson L, Stewart J, Ford M, Crawford M, Urban N, O'Briant K, Nelson BH.  Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q. Int J Cancer. 2003 Mar 10;104(1):73-84.

2002

McIntosh M, Urban N, Karlan B. Generating Longitudinal Screening Algorithms Using Novel Biomarkers for Disease. Cancer Epidemiol Biomarkers Prev. 2002 February 1, 2002;11(2):159-66.

2001

Hellstrom I, Ledbetter JA, Scholler N, Yang Y, Ye Z, Goodman G, Pullman J, Hayden-Ledbetter M, Hellstrom KE. CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer. Proc Natl Acad Sci USA. 2001;98(12):6783-8.

Publications by POCRC Investigators and DRP/CDP applicants

2008

Submitted:

Qiu J, Choi G, Faca V, Krasnoselsky A, Zhang Q, Zhang Y, Kooperberg C, McIntosh M, Hanash S. Discovery and validation of an autoantibody response to CSTF2 in ovarian cancer using a protein microarray approach. [Submitted to Clin Cancer Res].

In Press:

Elmore RG, Yevgeniya I, Scoles DR, Karlan BY, Li AJ. Impact of statin therapy on survival in epithelial ovarian cancer. [In Press, Gyn Onc].

McIntosh M, Anderson GL, Brown P, Coukos G, Drescher CW, Gambhir SS, Hanash S, Laird P, Nelson B, Palmer C, Urban N. Letter to the Editor: Reported ovarian cancer biomarker sensitivity is biased. [In Press, Clin Cancer Res].

Published:

Allison KH, Swisher EM, Kerkering KM, Garcia RL. Defining an appropriate threshold for the diagnosis of serous borderline tumor of the ovary: when is a full staging procedure unnecessary? Int J Gynecol Pathol. 2008 Jan;27(1):10-7.

Barua A, Abramowicz JS, Bitterman P, Bahr JM, Hales DB, Luborsky JL. OP17.08: Transvaginal ultrasound predicts ovarian tumor associated neo-angiogenesis. Ultrasound Obstet Gynecol. 2008 Aug 11;32(3):370.

Behrens MD, Wagner WM, Krco CJ, Erskine CL, Kalli KR, Krempski J, Gad EA, Disis ML, Knutson KL. The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. Blood. 2008 Feb 1;111(3):1472-9.

Chisholm KM, Goff BA, Garcia R, King MC, Swisher EM. Genomic structure of chromosome 17 deletions in BRCA1-associated ovarian cancers. Cancer Genet Cytogenet. 2008 May;183(1):41-8.

Faca VM, Ventura AP, Fitzgibbon MP, Pereira-Faca SR, Pitteri SJ, Green AE, Ireton RC, Zhang Q, Wang H, O'Briant KC, Drescher CW, Schummer M, McIntosh MW, Knudsen BS, Hanash SM. Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS ONE. 2008 June 18;3(6):e2425.

Faca VM, Song KS, Wang H, Zhang Q, Krasnoselsky AL, Newcomb LF, Plentz RR, Gurumurthy S, Redston MS, Pitteri SJ, Pereira-Faca SR, Ireton RC, Katayama H, Glukhova V, Phanstiel D, Brenner DE, Anderson MA, Misek D, Scholler N, Urban ND, Barnett MJ, Edelstein C, Goodman GE, Thornquist MD, McIntosh MW, DePinho RA, Bardeesy N, Hanash SM. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Medicine 2008 June 10;5 (6), p. e123.

Fejzo MS, Dering J, Ginther C, Anderson L, Ramos L, Walsh C, Karlan B, Slamon DJ. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target. Genes Chromosomes Cancer. 2008 Jul 9.

Fitzgibbon M, Li Q, McIntosh M. Modes of inference for evaluating the confidence of Peptide identifications. J Proteome Res. 2008 Jan;7(1):35-9.

Goodell V, Waisman J, Salazar LG, de la Rosa C, Link J, Coveler AL, Childs JS, Fintak PA, Higgins DM, Disis ML. Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Mol Cancer Ther. 2008 Mar;7(3):449-54.

Hales DB, Zhuge Y, Lagman JA, Ansenberger K, Mahon C, Barua A, Luborsky JL, Bahr JM. Cyclooxygenases expression and distribution in the normal ovary and their role in ovarian cancer in the domestic hen (Gallus domesticus). Endocrine. 2008 May 23.

Hannibal CG, Rossing MA, Wicklund KG, Cushing-Haugen KL. Analgesic drug use and risk of epithelial ovarian cancer. Am J Epidemiol. 2008 Jun 15;167(12):1430-7.

Hellstrom I, Friedman E, Verch T, Yang Y, Korach J, Jaffar J, Swisher E, Zhang B, Ben-Baruch G, Tan MC, Goedegebuure P, Hellstrom KE. Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients. Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1520-6.

Hellstrom I, Hellstrom KE. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Adv Exp Med Biol. 2008;622:15-21.

Karlan BY. Improving efficiencies in translational science. Gynecol Oncol. 2008 Mar;108(3):461.

Karlan BY, McIntosh M. The quest for ovarian cancer's Holy Grail: can CA-125 still be the chalice of early detection? J Clin Oncol. 2007; 25 (11):1303-4.

Li AJ, Scoles DR, Armstrong KU, Karlan BY. Androgen receptor cytosine-adenine-guanine repeat polymorphisms modulate EGFR signaling in epithelial ovarian carcinomas. Gynecol Oncol. 2008 Mar 26; [Epub ahead of print]

Lu H, Goodell V, Disis ML. Humoral Immunity Directed against Tumor-Associated Antigens As Potential Biomarkers for the Early Diagnosis of Cancer. J Proteome Res. 2008 Apr;7(4):1388-94.

Prentice RL, Anderson GL. The women’s health initiative: lessons learned. 2008:29:131-50.

Rossing MA, Cushing-Haugen KL, Doherty JA, Wicklund KG. Characteristics Related to the Maternal Intrauterine Environment and Risk of Epithelial Ovarian Cancer. Ann Epidemiol. 2008 May;18(5):411-5.

Rossing MA, Cushing-Haugen KL, Wicklund KG, Weiss NS. Cigarette smoking and risk of epithelial ovarian cancer. Cancer Causes Control. 2008 May;19(4):413-20.

Shah CA, Allison KH, Garcia RL, Gray HJ, Goff BA, Swisher EM. Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. Gynecol Oncol. 2008 May;109(2):215-9.

Song YJ, Kristal AR, Wicklund KG, Cushing-Haugen KL, Rossing MA. Coffee, tea, colas, and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):712-6.

Stammer K, Edassery SL, Barua A, Bitterman P, Bahr JM, Hales DB, Luborsky JL. Selenium-Binding Protein 1 expression in ovaries and ovarian tumors in the laying hen, a spontaneous model of human ovarian cancer. Gynecol Oncol. 2008 Apr;109(1):115-21.

Urban N, Drescher C. Potential and limitations in early diagnosis of ovarian cancer. Advances in Experimental Medicine and Biology. 2008 ;622:3-14.

Veljovich DS, Paley PJ, Drescher CW, Everett EN, Shah C, Peters WA, 3rd. Robotic surgery in gynecologic oncology: program initiation and outcomes after the first year with comparison with laparotomy for endometrial cancer staging. Am J Obstet Gynecol. 2008 Jun;198(6):679 e1-9; discussion  e9-10.

2007

Andersen MR, Drescher C, Zheng Y, Bowen D, Wilson S, Young A, McIntosh M, Mahony B, Lowe K, Urban N. Changes in cancer worry associated with participation in ovarian cancer screening. Psycho-Oncology. 2007 Sep;16(9):814-820.

Anderson GL, Kooperberg C, Geller N, Rossouw JE, Pettinger M, Prentice RL. Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials. Clin Trials. 2007; 4 (3):207-17.

Axtell AE, Lee MH, Bristow RE, Dowdy SC, Cliby WA, Raman S, Weaver JP, Gabbay M, Ngo M, Lentz S, Cass I, Li AJ, Karlan BY, Holschneider CH. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol. 2007; 25 (4):384-9.

Cimbaluk D, Rotmensch J, Scudiere J, Gown A, Bitterman P. Uterine carcinosarcoma: Immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. Gynecol Oncol. 2007;105(1):138-44.

Dang Y, Knutson KL, Goodell V, dela Rosa C, Salazar LG, Higgins D, Childs J, Disis ML. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming. Clin Cancer Res. 2007;13(6):1883-91.

DelloRusso C, Welcsh PL, Wang W, Garcia RL, King M-C, Swisher EM. Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation. Mol Cancer Res. 2007; 5(1): 35-45.

Disis ML. Translational Oncology: Transforming Cancer Care. J Clin Oncol. [10.1200/JCO.2007.11.0387]. 2007 March 1, 2007;25(7):750.

Faca V, Pitteri SJ, Newcomb L, Glukhova V, Phanstiel D, Krasnoselsky A, Zhang Q, Struthers J, Wang H, Eng J, Fitzgibbon M, McIntosh MW, Hanash S. Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes. J Proteome Res. 2007; 6 (9):3558-65.

Galic V, Willner J, Wollan M, Garg R, Garcia R, Goff B, Gray H, Swisher E. Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes Chromosomes Cancer. 2007; 46 (3):239-47.

Ghanekar SA, Bhatia S, Ruitenberg JJ, DeLa Rosa C, Disis ML, Maino VC, Maecker HT, Waters CA. Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors. J Immune Based Ther Vaccines. 2007; 5:7.

Goodell V, dela Rosa C, Slota M, MacLeod B, Disis ML. Sensitivity and specificity of tritiated thymidine incorporation and ELISPOT assays in identifying antigen specific T cell immune responses. BMC Immunol. 2007; 8:21.

Gottlieb GS, Hawes SE, Nickle DC, Herbeck JT, Kiviat NB, Mullins JI, Sow PS. Presenting plasma HIV RNA level and rate of CD4 T-cell decline. JAMA. 2007; 297 (8):805; author reply 6-7.

Holt SK, Rossing MA, Malone KE, Schwartz SM, Weiss NS, Chen C. Ovarian cancer risk and polymorphisms involved in estrogen catabolism. Cancer Epidemiol Biomarkers Prev. 2007; 16 (3):481-9.

Jacquemont C, Taniguchi T.  Proteasome function is required for DNA damage response and Fanconi anemia pathway activation.  Cancer Research, 2007 Aug; 67(15):7395-405.

Karlan BY, Berchuck A, Mutch D. The role of genetic testing for cancer susceptibility in gynecologic practice.Obstet Gynecol. 2007 Jul;110(1):155-67. Review.

Karlan BY. Can lifestyle influence genetics? Nat Clin Pract Oncol. 2007 Oct;4(10):555.

Karam AK, Santillan A, Bristow RE, Giuntoli II R, Gardner GJ, Cass I, Karlan BY, Li AJ. Tertiary cytoreductive surgery in recurrent ovarian cancer: Selection criteria and survival outcome. Gynecol Oncol. 2007; 104 (2):377-80.

Knutson KL, Disis ML, Salazar LG. CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Immunother. 2007; 56 (3):271-85. Review.

Lancaster JM, Powell CB, Kauff ND, Cass I, Chen LM, Lu KH, Mutch DG, Berchuck A, Karlan BY, Herzog TJ. Society of Gynecologic Oncologists Education Committee. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2007 Nov;107(2):159-62.

Lerner DL, Walsh CS, Cass I, Karlan BY, Li AJ. The prognostic significance of thrombocytosis in uterine papillary serous carcinomas. Gynecol Oncol. 2007; 104 (1):91-4.

Li AJ, Elmore RG, Pavelka JC, Karlan BY. Hyperandrogenism, mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biology. Gynecol Oncol. 2007 Dec;107(3):420-3.

Loch CM, Ramirez AB, Liu Y, Sather CL, Delrow JJ, Scholler N, Garvik BM, Urban ND, McIntosh MW, Lampe PD. Use of high density antibody arrays to validate and discover cancer serum biomarkers. Molecular Oncology. 2007 Dec;1 (3):313-20.

Lockyer HM, Tran E, Nelson BH. STAT5 is essential for Akt/p70S6 kinase activity during IL-2-induced lymphocyte proliferation. J Immunol. 2007 Oct 15;179(8):5301-8.

Lutz AM, Ray P, Willmann JK, Drescher C, Gambhir SS. 2-Deoxy-2-[F-18]fluoro-D: -glucose accumulation in ovarian carcinoma cell lines. Mol Imaging Biol. 2007; 9 (5):260-6.

May D, Fitzgibbon M, Liu Y, Holzman T, Eng J, Kemp CJ, Whiteaker J, Paulovich A, McIntosh MW. A platform for accurate mass and time analyses of mass spectrometry data. J Proteome Res. 2007; 6 (7):2685-94.

McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, Lynch H, Karlan B, Fishman D, Rosen B, Neuhausen SL, Offit K, Kauff N, Domchek S, Tung N, Friedman E, Foulkes W, Sun P, Narod SA. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol. 2007; 8(1):26-34.

Pavelka JC, Li AJ, Karlan BY. Hereditary ovarian cancer--assessing risk and prevention strategies. Obstet Gynecol Clin North Am. 2007 Dec;34(4):651-65, vii-viii. Review.

Prentice RL, Thomson CA, Caan B, Hubbell FA, Anderson GL, Beresford SA, Pettinger M, Lane DS, Lessin L, Yasmeen S, Singh B, Khandekar J, Shikany JM, Satterfield S, Chlebowski RT. Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. J Natl Cancer Inst. 2007;99(20):1534-43.

Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS. Menopausal hormone therapy and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2548-56.

Salazar LG, Coveler AL, Swensen RE, Gooley TA, Goodell V, Schiffman K, Disis ML. Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers. Clin Immunol. 2007 Dec;125(3):275-80.

Santillan A, Karam AK, Li AJ, Giuntoli R, 2nd, Gardner GJ, Cass I, Karlan BY, Bristow RE. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol Oncol. 2007; 104 (3):686-90.

Scoles DR, Pavelka J, Cass I, Tran H, Baldwin RL, Armstrong K, Karlan BY. Characterization of CSOC 882, a novel immortalized ovarian cancer cell line expressing EGFR, HER2, and activated AKT. Gynecol Oncol. 2007; 104 (1):120-8.

Scholler N, Urban N. CA125 in ovarian cancer. Biomarkers in Medicine.2007 Dec;1(4):513-523. Review.

Swisher EM, King MC. Defining women at high risk of ovarian cancer. Cancer Res. 2007; 67 (6):2902; author reply -3.

Tuve S, Chen BM, Liu Y, Cheng TL, Toure P, Sow PS, Feng Q, Kiviat N, Strauss R, Ni S, Li ZY, Roffler SR, Lieber A. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res. 2007; 67 (12):5929-39.

Vang R, Gown AM, Farinola M, Barry TS, Wheeler DT, Yemelyanova A, Seidman JD, Judson K, Ronnett BM. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: Utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am J Surg Pathol. 2007; 31 (5):653-63.

Vang R, Gown AM, Zhao C, Barry TS, Isacson C, Richardson MS, Ronnett BM. Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary. Am J Surg Pathol. 2007; 31 (6):854-69.

Walsh CS, Karlan BY. Contemporary progress in ovarian cancer screening. Curr Oncol Rep. 2007 Nov;9(6):485-93.

Walsh CS, Miller CW, Karlan BY, Koeffler HP. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol. 2007; 104 (3):660-4.

Whiteaker JR, Zhang H, Eng JK, Fang R, Piening BD, Feng LC, Lorentzen TD, Schoenherr RM, Keane JF, Holzman T, Fitzgibbon M, Lin C, Cooke K, Liu T, Camp DG, 2nd, Anderson L, Watts J, Smith RD, McIntosh MW, Paulovich AG. Head-to-head comparison of serum fractionation techniques. J Proteome Res. 2007; 6 (2):828-36.

Willner J, Wurz K, Allison K, Galic V,Garcia R, Goff B, Swisher E. Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Human Pathol. 2007. 38(4): p. 607-13.

Yang T, Wall EM, Milne K, Theiss P, Watson P, Nelson BH. CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism. Clin Cancer Res. 2007 Dec 1;13(23):7172-80.

Yee C. Adoptive cellular therapy of cancer in general principles of tumor immunotherapy: Basic and clinical applications of tumor immunology. Kaufman H, ed. Kluwer Academic Publishers. Springer 2007.

2006

Baker SG, Kramer BS, McIntosh M, Patterson BH, Shyr Y, Skates S. Evaluating markers for the early detection of cancer: overview of study designs and methods. Clin Trials. 2006;3:43-56.

Balkwill FR, Ashworth A, Bast RC, Berek JS, Boyd J, Disis ML, Gabra H, Gore ME, Hamilton TC, Jacobs IJ, Kaye SB, Kohn EC, Mills GB, Urban ND. 10th Biennial Helene Harris Memorial Trust meeting. Cancer Res. 2006 Mar 15;66(6):2904-6.

Chirnomas D, Taniguchi T, de la Vega M, Vaidya AP, Vasserman M, Hartman AR, Kennedy R, Foster R, Mahoney J, Seiden MV, D'Andrea AD. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther. 2006; 5:952-61.

Curb JD, Prentice RL, Bray PF, Langer RD, Van Horn L, Barnabei VM, Bloch MJ, Cyr MG, Gass M, Lepine L, Rodabough RJ, Sidney S, Uwaifo GI, Rosendaal FR. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med. 2006;166(7):772-80.

Di Paolo NC, Tuve S, Ni S, Hellstrom KE, Hellstrom I, Lieber A. Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose Cyclophosphamide treatment on antitumor immune responses. Cancer Res 2006;66:960-9.

Disis ML, Rivkin SE, Baron A, Markman M, Connolly D, Ueland F, Kohn E, Trimble E, Berek JS. Progress in ovarian cancer research: proceedings of the 5th Biennial Ovarian Cancer Research Symposium. Int J Gynecol Cancer. 2006; 16 (2):463-9.

Erkanli A, Taylor DD, Dean D, Eksir F, Egger D, Geyer J, Nelson BH, Stone B, Fritsche HA, Roden RB. Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection. Cancer Res. 2006 Feb 1;66(3):1792-8.

Feng Q, Yu M, Kiviat NB. Molecular biomarkers for cancer detection in blood and bodily fluids. Crit Rev Clin Lab Sci. 2006; 43 (5):497-560.

Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P, Narod SA. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006; 296(2):185-92.

Friedman E, Kotsopoulos J, Lubinski J, Lynch HT, Ghadirian P, Neuhausen SL, Isaacs C, Weber B, Foulkes WD, Moller P, Rosen B, Kim-Sing C, Gershoni-Baruch R, Ainsworth P, Daly M, Tung N, Eisen A, Olopade OI, Karlan B, Saal HM, Garber JE, Rennert G, Gilchrist D, Eng C, Offit K, Osborne M, Sun P, Narod SA. The Hereditary Breast Cancer Clinical Study Group. Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res. 2006 Mar 21;8(2): R15

Garg R, Wollan M, Galic V, Garcia R, Goff BA, Gray HJ, Swisher E. Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma. Gynecol Oncol. 2006; 103 (3):793-6.

Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol. 2006; 24 (26):4324-32.

Guillem JG, Wood WC, Moley JF, Berchuck A, Karlan BY, Mutch DG, Gagel RF, Weitzel J, Morrow M, Weber BL, Giardiello F, Rodriguez-Bigas MA, Church J, Gruber S, Offit K. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. Ann Surg Oncol. 2006; 13 (10):1296-321.

Guillem JG, Wood WC, Moley JF, Berchuck A, Karlan BY, Mutch DG, Gagel RF, Weitzel J, Morrow M, Weber BL, Giardiello F, Rodriguez-Bigas MA, Church J, Gruber S, Offit K. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol. 2006; 24 (28):4642-60.

Hartwell L, Mankoff D, Paulovich A, Ramsey S, Swisher E. Cancer biomarkers: a systems approach. Nat Biotechnol. 2006; 24 (8):905-8.

Hoque MO, Feng Q, Toure P, Dem A, Critchlow CW, Hawes SE, Wood T, Jeronimo C, Rosenbaum E, Stern J, Yu M, Trink B, Kiviat NB, Sidransky D. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol. 2006; 24 (26):4262-9.

Knutson KL, Lu H, Stone B, Reiman JM, Behrens MD, Prosperi CM, Gad EA, Smorlesi A, Disis ML. Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol. 2006; 177:1526-33.

Knutson KL, Wagner W, Disis ML. Adoptive T cell therapy of solid cancers. Cancer Immunol Immunother. 2006;55:96-103. Review.

Lamb JD, Garcia RL, Goff BA, Paley PJ, Swisher EM. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am J Obstet Gynecol. 2006; 194 (6):1702-9.

Lu H, Knutson KL, Gad E, Disis ML. The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens. Cancer Res. 2006; 66 (19):9754-61.

Lyons GE, Roszkowski JJ, Man S, Yee C, Kast WM, Nishimura MI. T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells. Cancer Immunol Immunother. 2006 Sep;55(9):1142-50.

Nelson, BH.  Interleukin-2, regulatory T cells and tolerance. J Immunol. 2004;172:3983-8.

Ni S, Gaggar A, Di Paolo N, Li ZY, Liu Y, Strauss R, Sova P, Morihara J, Feng Q, Kiviat N, Toure P, Sow PS, Lieber A. Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting. Cancer Gene Ther. 2006;13:1072-81.

Pavelka JC, Brown RS, Karlan BY, Cass I, Leuchter RS, Lagasse LD, Li AJ. Effect of obesity on survival in epithelial ovarian cancer. Cancer. 2006; 107 (7):1520-4.

Ramsey SD, Yoon P, Moonesinghe R, Khoury MJ. Population-based study of the prevalence of family history of cancer: implications for cancer screening and prevention. Genet Med. 2006;8(9):571-5.

Ramsey SD, Veenstra DL, Garrison LP, Jr., Carlson R, Billings P, Carlson J, Sullivan SD. Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests. Am J Manag Care. 2006;12 (4):197-202.

Rauch A, Bellew M, Eng J, Fitzgibbon M, Holzman T, Hussey P, Igra M, Maclean B, Lin CW, Detter A, Fang R, Faca V, Gafken P, Zhang H, Whitaker J, States D, Hanash S, Paulovich A, McIntosh MW. Computational Proteomics Analysis System (CPAS): An extensible, open-source analytic system for evaluating and publishing proteomic data and high throughput biological experiments. J Proteome Res. 2006;5:112-21.

Rossing MA, Tang MT, Flagg EW, Weiss LK, Wicklund KG, Weiss NS. Body size and risk of epithelial ovarian cancer (United States). Cancer Causes Control. 2006; 17 (5):713-20.

Sato AH, Anderson GL, Urban N, McIntosh MW. Comparing adaptive and non-adaptive algorithms for cancer early detection with novel biomarkers. Cancer Biomark. 2006; 2 (3-4):151-62.

Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, Lane DS, Hubbell FA, Assaf AR, Sarto GE, Schenken RS, Yasmeen S, Lessin L, Chlebowski RT; WHI Investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 2006 Apr 12;295(14):1647-57.

Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML, Ostrand-Rosenberg S. Tumor cells transduced with the MHC Class II transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. Cancer Res. 2006; 66:1147-54.

Tuve S, Wang H, Ware C, Liu Y, Gaggar A, Bernt K, Shayakhmetov D, Li Z, Strauss R, Stone D, Lieber A. A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. J Virol. 2006; 80 (24):12109-20.

Urban N, Drescher C. Current and future developments in screening for ovarian cancer. Women's Health. [doi:10.2217/17455057.2.5.733]. 2006 September;2(5):733-42.

Vang R, Gown AM, Barry TS, Wheeler DT, Ronnett BM. Ovarian atypical proliferative (borderline) mucinous tumors: gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive. Int J Gynecol Pathol. 2006; 25 (1):83-9.

Vang R, Gown AM, Barry TS, Wheeler DT, Yemelyanova A, Seidman JD, Ronnett BM. Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Am J Surg Pathol. 2006; 30 (9):1130-9.

Vang R, Gown AM, Wu L-S-F, Barry TS, Wheeler DT, Yemelyanova A, Seidman JD, Ronnett BM. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol. 2006 Nov;19(11):1421-8.

Vang R, Gown AM, Barry TS, Wheeler DT, Ronnett BM. Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases. Mod Pathol. 2006; 19 (1):97-105.

Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006 Mar 22;295(12):1379-88.

Wei SH, Balch C, Paik HH, Kim YS, Baldwin RL, Liyanarachchi S, Li L, Wang Z, Wan JC, Davuluri RV, Karlan BY, Gifford G, Brown R, Kim S, Huang TH, Nephew KP. Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res. 2006; 12 (9):2788-94.

Yee C. Adoptive Immunotherapy: Recent advances in the use of antigen-specific T cells for the treatment of cancer. In Cancer Chemotherapy & Biological Response Modifiers Annual 23. Sondel P, ed. 2006.

Yee C. Adoptive T-cell therapy of cancer. Hematol Oncol Clin North Am. 2006; 20 (3):711-33.

Yee C. Tumor immunotherapy in the molecular biology of cancer, Ed. Spelengaris S, Blackwell Publishing, Malden MA. 2006.

Yaziji H, Battifora H, Barry TS, Hwang HC, Bacchi CE, McIntosh MW, Kussick SJ, Gown AM. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol. 2006 Apr;19(4):514-23.

Zhang H, Knutson KL, Hellstrom KE, Disis ML, Hellstrom I. Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion. Mol Cancer Ther. 2006;5:149-55.

2005

Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G. Phase I clinical study of pertuzumab, a novel her dimerization inhibitor, in patients with advanced cancer. J Clin Oncol. 2005;23: 2534-43.

Bast R, Lilja H, Urban N. Rimm DL, Fritsche H, Gray J, Veltri R, Klee G, Allen A, Kim N, Gutman S, Rubin MA, Hruszkewycz A. Translational crossroads for biomarkers. Clin Can Research. 2005 Sep 1;11(17):6103-8. Review.

Bernt KM, Ni S, Tieu AT, Lieber A. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy. Cancer Res. 2005; 65:4343-52.

Byrne JA, Balleine RL, Fejzo MS, Mercieca J, Chiew Y-E, Livnat Y, Heaps L, Peters GB, Byth K, Karlan BY, Slamon DJ, Harnett P, deFazio A. Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. Int J Cancer. 2005 Dec 20;117(6):1049-54.

Cass I, Holschneider C, Datta Nandini, Barbuto D, Walts A, Karlan B.  BRCA-mutation association fallopian tube carcinoma: a distinct clinical phenotype. Obstet Gynecol. 2005 Dec;106(6):1327-34.

Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, Lane D, Dolan NC, Paskett ED, McTiernan A, Hubbell FA, Adams-Campbell LL, Prentice R. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst. 2005 Mar 16;97(6):439-48.

Disis ML. Molecular targeting with cancer vaccines. J Clin Oncol 2005;23:4840-1.

Elkas JC, Berek JS, Leuchter R, Lagasse LD, Karlan BY. Lower urinary tract reconstruction with ileum in the treatment of gynecologic malignancies. Gynecol Oncol. 2005 May;97(2):685-92. Review.

Gass M, Anderson GL, Barad D. Concerns about published data from the estrogen-progestin (HT) arm of the WHI. Am J Obstet Gynecol. 2005 Jan;192(1):333.

Goodell V, Disis ML. Human tumor cell lysates as a protein source for the detection of cancer antigen-specific humoral immunity. J Immunol Methods. 2005; 299:129-38. 

Groh V, Li YQ, Cioca D, Hunder NN, Wang W, Riddell SR, Yee C, Spies T. Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells.  Proc Natl Acad Sci U S A. 2005 May 3;102(18):6461-6.

Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother. 2005 Aug;54(8):721-8.

Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI, Boyd J.  Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res. 2005 Apr 15;11(8):2875-8.

Li AJ, Giuntoli RL 2nd, Drake R, Byun SY, Rojas F, Barbuto D, Klipfel N, Edmonds P, Miller DS, Karlan BY.  Ovarian preservation in stage I low-grade endometrial stromal sarcomas. Obstet Gynecol. 2005 Dec;106(6):1304-8.

Li AJ, Karlan BY.  Androgen mediation of thrombocytosis in epithelial ovarian cancer biology. Clin Cancer Res. 2005 Nov 15;11(22):8015-8.

Li Y, Bleakley M, Yee C.  IL-21 Influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol. 2005 Aug 15;175(4):2261-9.

McIntosh M. Could high plasma bikunin predict a favorable outcome in ovarian cancer? Nat Clin Pract Oncol. 2005; 2: 502-3.

Montgomery RB, Makary E, Schiffman K, Goodell V, Disis ML.  Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. Cancer Res. 2005 Jan 15;65(2):650-6.

Pepe MS, Longton G. Standardizing diagnostic markers to evaluate and compare their performance. Epidemiology. 2005 Sep;16(5):598-603.

Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC Jr. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005 Nov; 99(2): 267-77.

Roszkowski JJ, Lyons GE, Kast WM, Yee C, Van Besien K, Nishimura MI. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res. 2005 Feb 15;65(4):1570-6.

Swisher EM, Wollan M, Mahtani SM, Willner JB, Garcia R, Goff BA, King MC.  Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. Am J Obstet Gynecol. 2005 Sep;193 (3 Pt 1): 662-7.

Yee C. Adoptive T cell therapy: Addressing challenges in cancer immunotherapy. J Transl Med. 2005 Apr 28;3(1):17.

2004

Agoff SN, Garcia RL, Goff B, Swisher E. Follow-up of in situ and early-stage fallopian tube carcinoma in patients undergoing prophylactic surgery for proven or suspected BRCA-1 or BRCA-2 mutations. Am J Surg Pathol. 2004 Aug;28(8):1112-4.

Andersen MR, Nelson J, Peacock S, Giedzinska A, Drescher C, Bowen D, Urban N. Worry about ovarian cancer risk, and use of screening by high-risk women: how you recruit affects what you find. Am J Med Genet. 2004 Aug 30;129A(2):130-5.

Andersen MR, Urban N, Ramsey S, Briss PA. Examining the cost-effectiveness of cancer screening promotion. Cancer. 2004 Sep 1;101 Suppl 5:1229-38.

Berek JS, Taylor PT, Gordon A, Cunningham MJ, Finkler N, Orr J Jr, Rivkin S, Schultes BC, Whiteside TL, Nicodemus CF. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol. 2004 Sep 1;22(17):3507-16.

Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L,  Zou W.  6+Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004 Sep;10(9):942-9.

Danke NA, Koelle DM, Yee C, Beheray S, Kwok WW.  Autoreactive T cells in healthy individuals. J Immunol. 2004 May 15;172(10):5967-72.

Disis ML, Goodell V, Schiffman K, Knutson KL. Humoral epitope spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J. Clin Immunol. 2004 Sep;24(5):571-8.  

Disis ML, Schiffman K, Guthrie K, Salazar LG, Knutson KL, Goodell V, dela Rosa C, Cheever MA. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine. J Clin Oncol. 2004 May 15;22(10):1916-25.

Drescher CW, Nelson J, Peacock S, Andersen MR, McIntosh MW, Urban N. Compliance of average- and intermediate-risk women to semiannual ovarian cancer screening. Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):600-6.

Hood L, Heath J R, Phelps M E, Lin B. Systems biology and new technologies enable predictive and preventative medicine. Science. 2004;306: 640-643.

Hwang H, Quenneville L, Yaziji H, Gown AM. Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin. Appl Immunohistochem Mol Morphol. 2004 Jun;12(2):122-6.

Karlan B.  Profiling the perpetrator. J Clin Oncol. 2004 Dec 1;22(23):4663-4.

Karlan BY.  Defining cancer risks for BRCA germline mutation carriers: implications for surgical prophylaxis. Gynecol Oncol. 2004 Feb;92(2):519-20.

Kaufman HL, Disis ML. Immune system versus tumor: shifting the balance in favor of DCs and effective immunity. J Clin Invest. 2004 Mar;113(5):664-7.

Knutson KL, Almand B, Dang Y, Disis ML.  Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res. 2004 Feb; 1;64(3):1146-51.

Knutson KL, Disis ML.  IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion. Clin Exp Immunol. 2004 Feb;135(2):322-9.

Li AJ, Madden AC, Cass I, Leuchter RS, Lagasse LD, Karlan BY.  The prognostic significance of thrombocytosis in epithelial ovarian carcinoma. Gynecol Oncol. 2004 Jan;92(1):211-4.

Liao X, Li Y, Bonini C, Nair S, Gilboa E, Greenberg PD, Yee C.  Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. Mol Ther. 2004 May;9(5):757-64.

Liede A, Karlan BY, Narod SA.  Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 2004 Feb 15;22(4):735-42. Review

Rossing MA, Tang MT, Flagg EW, Weiss LK, Wicklund KG. A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am J Epidemiol. 2004 Dec 1;160(11):1070-8.

Sabbatini P, Aghajanian C, Dizon D, Anderson S, Dupont J, Brown JV, Peters WA, Jacobs A, Mehdi A, Rivkin S, Eisenfeld AJ, Spriggs D. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J Clin Oncol. 2004 Nov 15;22(22):4523-31.

Swisher E. Comment on "Malignant mixed Mullerian tumor of the ovary: an argument for BRCA3 or a coincidental cluster of unconnected cancer". Gynecol Oncol. 2004 Dec;95(3):773-4; author reply 774.

Teague RM, Tempero RM, Thomas S, Kaja MK, Nelson BH. Proliferation and differentiation of CD8+ T cells in the absence of IL 2/15 receptor β chain expression or STAT5 activation. J Immunol.2004 Sep 1;173(5):3131-9.

2003

Anderson GL, Judd H, Kaunitz A, Barad D, Beresford S, Pettinger M, Liu J, McNeeley SG, Lopez AM.  Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures in the Women’s Health Initiative. JAMA. 2003;290:1739-48.

Anderson GL, Manson J, Wallace R, Lund B, Hall D, Davis S, Shumaker S, Wang CY, Stein E, Prentice RL.  Implementation of the Women's Health Initiative study design. Ann Epidemiol. 2003;13:S5-17.

Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, Danino M, Karlan BY, Slamon DJ.  Overexpression of AKT2/protein kinase Bbeta leads to up‑regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res. 2003: 63:196‑206.

Balkwill F, Bast RC, Berek J, Chenevix-Trench G, Gore M, Hamilton T, Jacobs I, Mills G, Souhami R, Urban N, Ursulic S, Smyth J.  Current research and treatment for epithelial ovarian cancer. A position paper from the Helene Harris Memorial Trust. Eur J Cancer. 2003 Sep;39(13):1818-27.

Bernt KM, Ni S, Li ZY, Shayakhmetov DM, Lieber A.  The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors. Mol Ther.2003;8: 746-55.

Boguski M, McIntosh MW. Biomedical informatics for Proteomics. Nature. 2003 Mar 13; 422 (6928): 233-7.

Brown JV 3rd, Peters WA 3rd, Rettenmaier MA, Graham CL, Smith MR, Drescher CW, Micha JP.  Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer. Gynecol Oncol. 2003 Feb;88(2):136-40.

Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA and Karlan BY. Improved survival in BRCA associated ovarian cancer. Cancer. 2003; 97: 2187-95.

Chen LM, Yamada SD, Fu YS, Baldwin RL, Karlan BY.  Molecular similarities between primary peritoneal and primary ovarian carcinomas. Int J Gynecol Cancer. 2003 Nov-Dec;13(6):749-55.

Disis ML, Rivkin S. Future directions in the management of ovarian cancer. Hematol Oncol Clin North Am. 2003 Aug;17(4):1075-85.

Disis ML, Schiffman K. Issues on Clinical Applications of Cancer Vaccines. J Immunother. 2001;24(2):104-5.

Disis ML, Schiffman K, Salazar LG, Knutson KL. Antigen specific cancer vaccines.  In: Perry MC, ed. ASCO Educational Book. Alexandria, VA: American Society of Clinical Oncology: 29-36, 2003.

Disis ML, Scholler N, Dahlin A, Pullman J, Knutson KL, Hellstrom KE, Hellstrom I.  Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity. Mol Cancer Ther. 2003 Oct;2(10):995-1002.

Disis ML, Shiota FM, McNeel DG, Knutson KL. Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens. Immunobiology. 2003;207(3):179-86.

Elkas JC, Holschneider CH, Katz B, Li AJ, Louie R,  McGonigle KF, Berek JS. The use of continuous infusion topotecan in persistent and recurrent ovarian cancer.  Int J Gynecol Cancer. 2003 Mar-Apr;13(2):138-41.

Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, Radich J, Anderson G, Hartwell L. The case for early detection. Nat Rev Cancer. 2003 Apr;3(4):243-52. Review.  

Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenovirus. Nat Med. 2003;9:1408-12.

Hellstrom KE, Hellstrom I.  Novel approaches to therapeutic cancer vaccines. Expert Rev Vaccines. 2003 Aug;2(4):517-32.

Ho WY, Blattman JN, Dossett ML, Yee C, Greenberg PD.  Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell. 2003 May;3(5):431-7. Review.

Knutson KL, Curiel TJ, Salazar L, Disis ML.  Immunologic principles and immunotherapeutic approaches in ovarian cancer. Hematol Oncol Clin North Am. 2003 Aug;17(4):1051-73.

Li AJ, Baldwin RL, Karlan BY.  Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures. Am J Obstet Gynecol. 2003 Jul;189(1):22-7.

Li AJ, Baldwin RL, Karlan BY.  Short androgen receptor allele length is a poor prognostic factor in epithelial ovarian carcinoma. Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3667-73.

Littman AJ, Rossing MA, Madeleine MM, Tang MT, Yasui Y. Association between late age at infectious mononucleosis, Epstein-Barr virus antibodies, and ovarian cancer risk. Scand J Infect Dis. 2003; 35(10): 728-35.

Modugno F, Moslehi R, Ness RB, Nelson DB, Belle S, Kant JA, Wheeler JE, Wonderlick A, Fishman D, Karlan B, Risch H, Cramer DW, Dube MP, Narod SA.  Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States). Cancer Causes Control. 2003 Jun;14(5):439-46.

Peethambaram PP, Cliby WA, Lubiniecki G, Clayton AC, Roche PC, Iturria SJ, Hartmann LC, Hellstrom I, Strome SE. Her-2/neu expression in ovarian cancer: pre- and postexposure to platinum chemotherapy. Gynecol Oncol. 2003 Apr;89(1):99-104.

Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I.  Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003 Nov 15;362(9396):1612-6.

Salazar LG, Fikes J, Southwood S, Ishioka G, Knutson KL, Gooley TA, Schiffman K, Disis ML.  Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res. 2003 Nov 15;9(15):5559-65.

Swisher E. Ovarian cancer associated with inherited mutations in BRCA1 or BRCA2. Curr Womens Health Rep. 2003 Feb;3(1):27-32. Review.

Swisher E. Prophylactic surgery and other strategies for reducing the risk of familial ovarian cancer. Curr Treat Options Oncol. 2003 Apr;4(2):105-10. Review.

Urban N.  Specific keynote: ovarian cancer risk assessment and the potential for early detection. Gynecol Oncol. 2003 Jan;88 (1 Pt 2):S75-9; discussion S80-3. Review.

Urban N, McIntosh M, Andersen MR, Karlan BY.  Ovarian Cancer Screening. Hematol Oncol Clin N Am. 2003 Aug;17(4):989-1005, ix.

2002

Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol. 2002;20(11):2624-32.

McIntosh MW, Pepe MS. Combining several screening tests: optimality of the risk score. Biometrics. 2002 Sep;58(3):657-64.

Scholler N, Hayden-Ledbetter M, Dahlin A, Hellstrom I, Hellstrom KE, Ledbetter JA. Cutting edge: CD83 regulates the development of cellular immunity. J Immunol. 2002;168(6):2599-602.

Urban N, McIntosh MW, Clarke L, Jacobs I, Karlan B, Anderson G, Drescher C. Socioeconomics of Ovarian Cancer Screening, Book chapter in Ovarian Cancer 6 , Oxford Press, 21 March, 2002.

Ye Z, Hellstrom I, Hayden-Ledbetter M, Dahlin A, Ledbetter JA, Hellstrom KE. Gene therapy for cancer using single-chain Fv fragments specific for 4- 1BB. Nat Med. 2002;8(4):343-8.

2001

Disis ML, Knutson KL, McNeel DG, Davis D, Schiffman K. Clinical translation of peptide-based vaccine trials: the HER-2/neu model. Crit Rev Immunol. 2001;21(1-3):263-73.

Disis ML, Schiffman K. Cancer vaccines targeting the HER2/neu oncogenic protein. Semin Oncol. 2001;28(6 Suppl 18):12-20.

Hellstrom I, Goodman G, Pullman J, Yang Y, Hellstrom KE. Overexpression of HER-2 in ovarian carcinomas. Cancer Res. 2001;61(6):2420-3.

Pauler D, Menon U, McIntosh M, Symecko H, Skates S, Jacobs I. Factors Influencing Serum CA125II Levels in Healthy Postmenopausal Women. Cancer Epidemiol Biomarkers Prev. 2001 May 1, 2001;10(5):489-93.

Scholler N, Hayden-Ledbetter M, Hellstrom KE, Hellstrom I, Ledbetter JA. CD83 is a sialic acid-binding Ig-like lectin (Siglec) adhesion receptor that binds monocytes and a subset of activated CD8+ T cells. J Immunol. 2001;166(6):3865-72.

Stone B, Schummer M, Paley PJ, Crawford M, Ford M, Urban N, Nelson BH. MAGE-F1, a novel ubiquitously expressed member of the MAGE superfamily. Gene. 2001;267(2):173-82.

2000

Ben-Dor A, Bruhn L, Friedman N, Nachman I, Schummer M, Yakhini Z. Tissue classification with gene expression profiles. J Comput Biol. 2000;7(3-4):559-83.

Furey TS, Cristianini N, Duffy N, Bednarski DW, Schummer M, Haussler D. Support vector machine classification and validation of cancer tissue samples using microarray expression data. Bioinformatics. 2000 October 1;16(10):906-14.

Keller A, Schummer M, Hood L, Ruzzo WL. (2000) Bayesian Classification of DNA Array Expression Data. Technical Report, UW-CSE-2000-08-01, August, 2000.

Montgomery RB, Guzman J, O'Rourke DM, Stahl WL. Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression. J Biol Chem. 2000;275(23):17358-63.

Schummer M, Kiviat N, Bednarski D, Crumb GK, Ben-Dor A, Drescher C, Hood L. Hybridization of an array of 100,000 cDNAs with 32 tissues finds potential ovarian cancer marker genes. Int J Biol Markers. 2000;15(Suppl. 1):35.

1999

Schummer M, Ng W, Bumgarner R, Nelson P, Schummer B, Bednarski D, Hassell L, Baldwin R, Karlan B, Hood L. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene. 1999 October 1;238(2):375-85.